The University of Chicago Header Logo

Connection

Stuart Sprague to Chronic Disease

This is a "connection" page, showing publications Stuart Sprague has written about Chronic Disease.
Connection Strength

0.595
  1. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010 Jul; 78(2):146-51.
    View in: PubMed
    Score: 0.064
  2. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8.
    View in: PubMed
    Score: 0.062
  3. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.060
  4. Advances in renal bone disease: osteoporosis and chronic kidney disease. Curr Rheumatol Rep. 2009 Jul; 11(3):185-90.
    View in: PubMed
    Score: 0.060
  5. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
    View in: PubMed
    Score: 0.057
  6. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S170-4.
    View in: PubMed
    Score: 0.057
  7. Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008 Jun; 73(11):1275-81.
    View in: PubMed
    Score: 0.055
  8. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis? Arch Intern Med. 2007 Jan 22; 167(2):115-6.
    View in: PubMed
    Score: 0.050
  9. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis. 2007 Jan; 14(1):27-36.
    View in: PubMed
    Score: 0.050
  10. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 Jun; 41(6):2500-2518.
    View in: PubMed
    Score: 0.042
  11. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45.
    View in: PubMed
    Score: 0.014
  12. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial. 2007 Jan-Feb; 20(1):24-32.
    View in: PubMed
    Score: 0.013
  13. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.